Profile data is unavailable for this security.
About the company
Destiny Pharma plc is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of novel medicines that can prevent life-threatening infections. The Company's drug development pipeline includes two late stage assets, NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.difficile infection (CDI) recurrence, which is the principal cause of hospital acquired infection in the United States, and XF-73 nasal gel, a proprietary drug targeting the prevention of postsurgical staphylococcal hospital infections including methicillin-resistant Staphylococcus aureus (MRSA). The Company’s earlier stage pipeline is focused on other indications including two, separate dermal programmes incorporating its XF platform. It is also collaborating with SporeGen on a novel SPOR-COV innate immune system boosting nasal spray for the prevention of COVID-19 and influenza.
- Revenue in GBP (TTM)0.00
- Net income in GBP-5.66m
- Incorporated1996
- Employees20.00
- LocationDestiny Pharma PLCSussex Innovation CentreScience Park Square, FalmerBRIGHTON BN1 9SBUnited KingdomGBR
- Phone+44 127 370 4440
- Fax+44 127 370 4414
- Websitehttps://www.destinypharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proteome Sciences plc | 5.03m | -2.44m | 9.92m | 35.00 | -- | -- | -- | 1.97 | -0.0083 | -0.0083 | 0.017 | -0.0104 | 0.4209 | 3.89 | 3.04 | 143,657.10 | -20.45 | -1.22 | -- | -- | 32.76 | 54.53 | -48.59 | -2.20 | 0.2667 | -2.03 | 1.29 | -- | -35.37 | 10.52 | -284.38 | -- | 126.22 | -- |
| Kanabo Group PLC | 895.00k | -7.99m | 11.07m | 20.00 | -- | 1.47 | -- | 12.37 | -0.0137 | -0.0137 | 0.0017 | 0.0119 | 0.0785 | 11.11 | 28.41 | -- | -70.12 | -75.83 | -77.61 | -83.33 | 14.97 | -- | -893.30 | -1,267.35 | 4.96 | -10.43 | 0.035 | -- | 48.42 | -- | -16.26 | -- | -- | -- |
| Shield Therapeutics PLC | 7.21m | -46.89m | 11.54m | 28.00 | -- | 0.3881 | -- | 1.60 | -0.1549 | -0.1549 | 0.0151 | 0.038 | 0.1691 | 1.80 | 0.9805 | -- | -109.95 | -42.77 | -129.39 | -48.12 | 44.76 | 79.44 | -650.12 | -274.35 | 2.64 | -124.94 | 0.1756 | -- | 261.55 | 53.86 | -151.04 | -- | -7.68 | -- |
| Chill Brands Group PLC | 146.62k | -3.64m | 11.64m | 2.00 | -- | -- | -- | 79.42 | -0.0142 | -0.0142 | 0.0006 | -0.0024 | 0.0319 | 0.0992 | 0.3639 | 73,310.00 | -79.21 | -72.55 | -141.46 | -105.35 | 53.05 | -- | -2,485.30 | -1,625.46 | 0.6499 | -8.48 | 1.17 | -- | -86.73 | -50.89 | 23.50 | -- | -35.95 | -- |
| Synairgen plc | 0.00 | -9.99m | 11.80m | 30.00 | -- | 0.7392 | -- | -- | -0.0496 | -0.0496 | 0.00 | 0.0793 | 0.00 | -- | -- | 0.00 | -41.40 | -54.75 | -48.86 | -60.72 | -- | -- | -- | -83,247.62 | -- | -- | 0.00 | -- | -- | -- | 63.74 | -- | 0.00 | -- |
| Abingdon Health PLC | 5.34m | -2.24m | 12.17m | 82.00 | -- | 6.71 | -- | 2.28 | -0.0184 | -0.0184 | 0.0439 | 0.0149 | 0.8978 | 7.67 | 4.74 | 65,170.73 | -37.55 | -51.31 | -58.04 | -79.85 | 57.35 | 33.16 | -41.82 | -139.64 | 1.59 | -- | 0.3572 | -- | 42.68 | -- | 83.77 | -- | -- | -- |
| Provexis plc | 598.08k | -496.59k | 13.01m | 2.00 | -- | 12.97 | -- | 21.76 | -0.0002 | -0.0002 | 0.0003 | 0.0004 | 0.6717 | 3.04 | 2.95 | 299,040.00 | -55.78 | -48.82 | -41.86 | -33.68 | 46.72 | 86.14 | -83.03 | -97.64 | 1.96 | -- | 0.00 | -- | -8.51 | 10.58 | -71.79 | -- | -- | -- |
| Incanthera PLC | 0.00 | -1.48m | 13.40m | 8.00 | -- | -- | -- | -- | -0.0192 | -0.0192 | 0.00 | -0.0086 | 0.00 | -- | -- | 0.00 | -373.20 | -101.74 | -- | -132.88 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -36.11 | -- | -- | -- |
| Genincode PLC | 1.72m | -6.73m | 16.37m | 28.00 | -- | 1.86 | -- | 9.54 | -0.0703 | -0.0703 | 0.0179 | 0.0497 | 0.168 | 16.36 | 2.88 | 61,285.71 | -65.92 | -- | -72.37 | -- | 47.55 | -- | -392.31 | -- | 5.85 | -- | 0.0632 | -- | 23.92 | -- | -34.21 | -- | -- | -- |
| Destiny Pharma PLC | 0.00 | -5.66m | 16.68m | 20.00 | -- | 1.81 | -- | -- | -0.0624 | -0.0624 | 0.00 | 0.0965 | 0.00 | -- | -- | -- | -60.33 | -54.32 | -67.28 | -59.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 13.02 | -- | 35.39 | -- |
| LungLife AI Inc | 36.74k | -4.32m | 17.13m | 15.00 | -- | 1.05 | -- | 466.39 | -0.1696 | -0.1696 | 0.0014 | 0.248 | 0.0038 | -- | 0.2831 | 2,449.01 | -44.11 | -- | -50.09 | -- | 100.00 | -- | -11,767.39 | -- | -- | -- | 0.0419 | -- | 91.67 | -- | 28.83 | -- | -- | -- |
| OptiBiotix Health PLC | 689.10k | -13.17m | 17.14m | 3.00 | -- | 1.70 | -- | 24.87 | -0.1489 | -0.1489 | 0.0078 | 0.1029 | 0.0426 | 2.28 | 1.25 | 229,700.00 | -81.35 | 17.83 | -83.43 | 18.66 | 49.31 | 54.87 | -1,911.88 | 190.54 | 3.24 | -0.089 | 0.00 | -- | -79.35 | 19.05 | -58.68 | 6.28 | 30.03 | -- |
| Skinbiotherapeutics PLC | 161.65k | -2.88m | 17.73m | 11.00 | -- | 4.61 | -- | 109.70 | -0.0165 | -0.0165 | 0.0009 | 0.0192 | 0.0522 | 0.8871 | 0.4181 | 14,695.45 | -93.07 | -52.07 | -115.26 | -57.33 | 62.90 | -- | -1,784.70 | -4,694.37 | 6.48 | -379.78 | 0.0259 | -- | 76.65 | -- | -1.52 | -- | 18.00 | -- |
| Oncimmune Holdings PLC | 1.15m | -6.15m | 17.79m | 56.00 | -- | 27.08 | -- | 15.45 | -0.0859 | 0.0507 | 0.0159 | 0.0089 | 0.1239 | 1.08 | 0.5941 | -- | -66.15 | -- | -131.46 | -- | 68.75 | -- | -533.94 | -- | 3.75 | -1.96 | 0.8897 | -- | -- | -- | -- | -- | -- | -- |
| Verici DX PLC | 15.17k | -8.95m | 18.15m | 14.00 | -- | 2.39 | -- | 1,196.36 | -0.0526 | -0.0526 | 0.00009 | 0.0314 | 0.0013 | -- | 0.1152 | 1,011.55 | -77.76 | -- | -92.28 | -- | 84.21 | -- | -59,015.79 | -- | -- | -- | 0.0232 | -- | -- | -- | -36.94 | -- | -- | -- |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -6.69m | 20.46m | 17.00 | -- | 6.36 | -- | -- | -0.0061 | -0.0061 | 0.00 | 0.0024 | 0.00 | -- | -- | 0.00 | -101.47 | -82.19 | -112.85 | -95.97 | -- | -- | -- | -- | -- | -28.03 | 0.5144 | -- | -- | -- | -68.14 | -- | 36.68 | -- |
Data as of May 09 2024. Currency figures normalised to Destiny Pharma PLC's reporting currency: UK Pound GBX
19.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rathbones Investment Management Ltd.as of 02 Jan 2024 | 5.22m | 5.48% |
| Unicorn Asset Management Ltd.as of 01 Mar 2023 | 4.08m | 4.28% |
| Hargreaves Lansdown Asset Management Ltd.as of 02 Jan 2024 | 2.72m | 2.85% |
| KW Investment Management Ltd.as of 02 Jan 2024 | 2.36m | 2.48% |
| Jarvis Investment Management Ltd.as of 02 Jan 2024 | 1.21m | 1.27% |
| Evelyn Partners Investment Management Services Ltd.as of 02 Jan 2024 | 925.00k | 0.97% |
| IG Markets Ltd.as of 02 Jan 2024 | 846.00k | 0.89% |
| HSBC Global Asset Management (UK) Ltd.as of 02 Jan 2024 | 610.00k | 0.64% |
| James Brearley & Sons Ltd.as of 02 Jan 2024 | 397.00k | 0.42% |
| Oberon Investments Ltd. (GB Investment Management)as of 02 Jan 2024 | 326.00k | 0.34% |
More ▼
Data from 31 Dec 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
